- PA5-32330 - Invitrogen Antibodies CD68 antibody

Submitted references Acute minocycline administration reduces brain injury and improves long-term functional outcomes after delayed hypoxemia following traumatic brain injury.

Celorrio M, Shumilov K, Payne C, Vadivelu S, Friess SH
Acta neuropathologica communications 2022 Jan 28;10(1):10

Different Innate Immune Responses in BALB/c and C57BL/6 Strains following Corneal Transplantation.

Bleul T, Zhuang X, Hildebrand A, Lange C, Böhringer D, Schlunck G, Reinhard T, Lapp T
Journal of innate immunity 2021;13(1):49-59

Dynamic Leukocyte Populations Are Associated With Early- and Late-stage Lesions in Hidradenitis Suppurativa.

Altman SR, Criswell SL
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2021 Mar;69(3):191-201

High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.

He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W
PloS one 2013;8(12):e79769

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of SY5Y Cells using anti-CD68 Polyclonal Antibody (Product # PA5-32330). The recommened dilution for this antibody in western blot applications is 1:25.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot was performed using Anti-CD68 Polyclonal Antibody (Product # PA5-32330) and an 80 & 130 kDa band corresponding to Cd68 was observed in THP-1 and K-562 cells but not in Jurkat and Raji. Whole cell extracts (60 µg lysate, without adding DDT and boiling) of THP-1 (Lane 1), K-562 (Lane 2), Jurkat (Lane 3) and Raji (Lane 4) were electrophoresed using NuPAGE™ 10% Bis-Tris Protein Gel (Product # NP0301BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # LC2001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036,1:4000 dilution) using the iBright™ FL1500 Imaging System (Product # A44115). Chemiluminescentdetection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of CD68 using anti-CD68 Polyclonal Antibody (Product # PA5-32330) in Tonsil Tissue. The recommened dilution for this antibody in immunohistochemistry applications is 1:100.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Distribution characteristics of CD68 + COX-2 + TAMs in the ovarian cancer tissue. ( A ) CD68 + COX-2 + TAMs in a representative cancer tissue section from the high MUC2 expression group were shown. ( B ) CD68 + COX-2 + TAMs in a representative cancer tissue section from the low MUC2 expression group were shown. Nuclei were stained with SYTO 40, shown in purple. Arrowhead, CD68 + COX-2 + TAMs. Arrow, CD68 + COX-2 - TAMs. Asterisk, COX-2 + cancer cells (CD68 - ) surrounding the CD68 + COX-2 + TAMs. ( C ) The intratumoral densities of CD68 + TAMs and CD68 + COX-2 + TAMs and the CD68 + COX-2 + /CD68 + TAM ratios of the high and low MUC2 expression groups were compared, as were the corresponding values for the cancer islet and stromal regions. It could be found that the ratio of CD68 + COX-2 + /CD68 + TAMs was significantly higher in the high MUC2 expression group than in the low MUC2 expression group *, p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Correlation of the COX-2 expression statuses of the cancer cells and TAMs. ( A ) Representative microscopic fields in cancer tissue sections from the high and low MUC2 expression groups. In the cancer tissue sections from the high MUC2 expression group, COX-2 + cancer cells and COX-2 + TAMs (with cytoplasm in red) were frequently distributed throughout the entire islet region, whereas in the cancer tissue from the low MUC2 expression group, COX-2 + cancer cells and COX-2 + TAMs were both observed less frequently. Arrow, CD68 + TAMs (left, CD68 + COX-2 + TAMs in purple; right, CD68 + COX-2 - TAMs in brown). Scale bar, 50 mum. ( B ) Comparison of the COX-2 + cancer cell densities between the high and low MUC2 expression groups. *, p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Total CD68 + TAMs and their M1 and M2 subsets in the ovarian cancer tissue. ( A ) Representative MUC2 and CD68 single-immunostained and CD68/HLA-DR, CD68/iNOS, CD68/CD163, CD68/VEGF double-immunostained sections from the high MUC2 expression group. ( B ) Representative MUC2 and CD68 single-immunostained and CD68/HLA-DR, CD68/iNOS, CD68/CD163, CD68/VEGF double-immunostained sections from the low MUC2 expression group. For VEGF- and iNOS-immunostaining, cancer cells (in red) that independently expressed these two proteins can be found in the cancer tissue sections from both groups (arrowhead). Asterisk, TAMs (in brown) that expressed the CD68 protein. Arrow, CD68 + TAMs (in purple) that co-expressed the indicated proteins (HLA-DR, iNOS, CD163 or VEGF). Scale bar (black), 100 mum. Inset scale bar (white), 10 mum. ( C ) Comparison of the percentages of different M1 and M2 cell subsets (i.e., M1/M2 distribution patterns) among all the TAMs. It could be noted that the percentages of M1 macrophages were significantly higher than those of M2 macrophages in the high MUC2 expression group; but on the contrary, the percentages of M1 macrophages were significantly lower than those of M2 macrophages in the low MUC2 expression group. *, p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 M1 and M2 distribution patterns of the COX-2 + TAMs in the high and low MUC2 expression groups. ( A ) Representative CD68, COX-2 and M1/M2 signature triple-immunostained sections are shown. Arrowhead, COX-2 + TAMs that expressed the M1 or M2 signatures. Yellow arrow, COX-2 + TAMs that did not express the M1 or M2 signature indices. Blue arrow, COX-2 - M1 or M2 TAMs. Asterisk, COX-2 + cancer cells. Scale bar, 10 mum. ( B ) The percentages of M1- and M2-polarized TAMs in the CD68 + COX-2 + TAM populations that infiltrated the cancer tissue in the two MUC2 expression-level groups were compared. ( C ) The percentages of COX-2 + cells in the M1 and M2 populations of the intratumoral TAMs in the two MUC2 expression-level groups were compared. It could be noted that most of the COX-2 + TAMs in both the high and low MUC2 expression groups exhibited M2 signatures (i.e., CD163 + and VEGF + ). *, p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4. Examples of immunohistochemistry of corneal transplants 18 to 21 days after transplantation. a-d The epithelium is located at the top of the image and the endothelium at the bottom. Anti-mouse F4/80 (red, first row) and anti-mouse CD38 (green, second row) antibodies were used to identify M1 macrophages. DAPI (blue) was used for nuclear staining. The box plots ( e ) represent the percentages of CD38 + cells among the F4/80 + macrophages as shown in a-d . The percentages of CD38 + cells among the F4/80 + cells were counted from the immunohistochemical slides as above ( n = 3 animals were analyzed for the calculation, except n = 4 in the allogeneic BALB/c group). Statistics were calculated using the Kruskal-Wallis test; the results are presented as mean+-SEM. In untreated, non-transplanted mice, only sparse CD68 + or F4/80 + cells can be detected, that do not stain for CD38 ( f ).

PA5-32330

Antibody data